[go: up one dir, main page]

WO2014118649A3 - Compositions and methods for the treatment of cardiovascular diseases - Google Patents

Compositions and methods for the treatment of cardiovascular diseases Download PDF

Info

Publication number
WO2014118649A3
WO2014118649A3 PCT/IB2014/058090 IB2014058090W WO2014118649A3 WO 2014118649 A3 WO2014118649 A3 WO 2014118649A3 IB 2014058090 W IB2014058090 W IB 2014058090W WO 2014118649 A3 WO2014118649 A3 WO 2014118649A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
treatment
methods
cardiovascular diseases
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2014/058090
Other languages
French (fr)
Other versions
WO2014118649A2 (en
Inventor
Mahesh Kandula
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cellix Bio Pvt Ltd
Original Assignee
Cellix Bio Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IB2013/052246 external-priority patent/WO2013168022A1/en
Priority claimed from PCT/IB2013/052328 external-priority patent/WO2013168024A1/en
Application filed by Cellix Bio Pvt Ltd filed Critical Cellix Bio Pvt Ltd
Publication of WO2014118649A2 publication Critical patent/WO2014118649A2/en
Anticipated expiration legal-status Critical
Publication of WO2014118649A3 publication Critical patent/WO2014118649A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/54—Sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for treating or preventing atherothrombosis may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment or management of ischemia, stroke, cerebral thrombosis, arterial thrombosis, thrombotic cerebrovascular, cardiovascular diseases and blood clots.
PCT/IB2014/058090 2013-01-19 2014-01-07 Compositions and methods for the treatment of cardiovascular diseases Ceased WO2014118649A2 (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
IN252/CHE/2013 2013-01-19
IN252CH2013 2013-01-19
IN253CH2013 2013-01-20
IN253/CHE/2013 2013-01-20
PCT/IB2013/052246 WO2013168022A1 (en) 2012-05-08 2013-03-21 Compositions and methods for treating atherothrombosis
IBPCT/IB2013/052246 2013-03-21
IBPCT/IB2013/052328 2013-03-24
PCT/IB2013/052328 WO2013168024A1 (en) 2012-05-07 2013-03-24 Prodrugs of anti-platelet agents

Publications (2)

Publication Number Publication Date
WO2014118649A2 WO2014118649A2 (en) 2014-08-07
WO2014118649A3 true WO2014118649A3 (en) 2017-03-23

Family

ID=51263080

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2014/058090 Ceased WO2014118649A2 (en) 2013-01-19 2014-01-07 Compositions and methods for the treatment of cardiovascular diseases

Country Status (1)

Country Link
WO (1) WO2014118649A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111848497A (en) * 2020-07-28 2020-10-30 内蒙古医科大学 Clopidogrel active metabolite derivative, its prodrug and its preparation method and application

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0934928A1 (en) * 1996-08-28 1999-08-11 Sankyo Company Limited Cyclic amine derivatives

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0934928A1 (en) * 1996-08-28 1999-08-11 Sankyo Company Limited Cyclic amine derivatives

Also Published As

Publication number Publication date
WO2014118649A2 (en) 2014-08-07

Similar Documents

Publication Publication Date Title
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
NZ738187A (en) Tricyclic derivative compound, method for preparing same, and pharmaceutical composition comprising same
PH12015502443A1 (en) 6-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
UA98373C2 (en) Condensed heterocyclic compounds and use thereof as c-met inhibitors
WO2014179564A8 (en) Thiazolopyrrolidine inhibitors of ror-gamma
MX2015011077A (en) Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders.
EA201491028A8 (en) METHOD OF OBTAINING SUBSTITUTED 5-FLUOR-1H-PYRAZOLOPIRIDINES
HK1206021A1 (en) Novel ring-substituted n-pyridinyl amides as kinase inhibitors
WO2013175377A3 (en) Compositions and methods for treatment of mucositis
MX2016008665A (en) 1,2-naphthoquinone derivative and method for preparing same.
WO2014172188A3 (en) 4-pyridone derivative compounds and uses thereof as hiv integrase inhibitors
WO2013175376A3 (en) Compositions and methods for the treatment of local pain
WO2014068463A3 (en) Compositions and methods for the treatment of inflammation and metabolic disorders
WO2014091384A3 (en) Compositions and methods for the treatment of mucositis
WO2016046680A3 (en) Compositions and methods for the treatment of liver metabolic diseases
MX2017013099A (en) Methods for the treatment of inflammatory disorders.
WO2013175359A3 (en) Compositions and methods for the treatment of multiple sclerosis
MX2022005523A (en) Compositions and methods for the treatment of fungal infections.
WO2014087323A3 (en) Compounds and compositions for the treatment of autoimmune and chronic metabolic diseases
WO2014006529A3 (en) Compositions and methods for the treatment of moderate to severe pain
EA201492256A1 (en) PROCARE OF 5- (5-PHENYL-4- (Pyridine-2-Ilmethylamino) Quinazoline-2-IL) Pyridine-3-Sulfonamide Based on Phosphoramide Acid
WO2014118649A3 (en) Compositions and methods for the treatment of cardiovascular diseases
WO2014097137A3 (en) Compositions and methods for the treatment of seizures and neurologic diseases
MX386902B (en) METHODS FOR THE TREATMENT OF CARDIOVASCULAR DISORDERS.
WO2013167989A3 (en) Compositions and methods for the treatment of neurological disorders

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14746913

Country of ref document: EP

Kind code of ref document: A2